Juvenile Idiopathic Arthritis.
The New England journal of medicine. 2025 Jul; 393(Jul):162-174. doi: 10.1056/NEJMra2402073. pii: .
Base: PUBMEDTropical pyomyositis.
Best practice & research. Clinical rheumatology. 2025 May; 39(May):102041. doi: 10.1016/j.berh.2025.102041. pii: S1521-6942(25)00009-9.
Base: PUBMEDAutoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Rheumatic diseases clinics of North America. 2025 May; 51(May):347-359. doi: 10.1016/j.rdc.2025.01.008. pii: S0889-857X(25)00008-0.
Base: PUBMEDNewer Immunosuppressants for Rheumatologic Disease: Preoperative Considerations.
Rheumatic diseases clinics of North America. 2025 May; 51(May):383-395. doi: 10.1016/j.rdc.2025.01.010. pii: S0889-857X(25)00010-9.
Base: PUBMEDUrine Protein Tests in Systemic Lupus Erythematosus: What Do They Mean?
The Journal of rheumatology. 2025 Apr; 52(Apr):308-315. doi: 10.3899/jrheum.2024-0910. pii: .
Base: PUBMEDExpert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.
Annals of the rheumatic diseases. 2025 May; 84(May):664-679. doi: 10.1016/j.ard.2025.01.032. pii: S0003-4967(25)00181-5.
Base: PUBMEDExpert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy.
Arthritis & rheumatology (Hoboken, N.J.). 2025 May; 77(May):506-520. doi: 10.1002/art.43057. pii: .
Base: PUBMEDClinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project.
Arthritis & rheumatology (Hoboken, N.J.). 2025 Apr; 77(Apr):477-489. doi: 10.1002/art.43038. pii: .
Base: PUBMEDRecommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology.
Arthritis & rheumatology (Hoboken, N.J.). 2025 Apr; 77(Apr):383-389. doi: 10.1002/art.43050. pii: .
Base: PUBMEDThe Assessment of SpondyloArthritis International Society (ASAS) Consensus-Based Expert Definition of Difficult-to-Manage, including Treatment-Refractory, Axial Spondyloarthritis.
Annals of the rheumatic diseases. 2025 Apr; 84(Apr):538-546. doi: 10.1016/j.ard.2025.01.035. pii: S0003-4967(25)00185-2.
Base: PUBMEDA Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
The New England journal of medicine. 2025 May; 392(May):2013-2024. doi: 10.1056/NEJMoa2413449. pii: .
Base: PUBMEDArthritis related to parasitic infections.
Best practice & research. Clinical rheumatology. 2025 May; 39(May):102062. doi: 10.1016/j.berh.2025.102062. pii: S1521-6942(25)00030-0.
Base: PUBMEDManagement of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies.
Current opinion in rheumatology. 2025 May; 37(May):167-175. doi: 10.1097/BOR.0000000000001082. pii: .
Base: PUBMEDTGFβ links EBV to multisystem inflammatory syndrome in children.
Nature. 2025 Apr; 640(Apr):762-771. doi: 10.1038/s41586-025-08697-6. pii: .
Base: PUBMEDIgG4-related disease and other fibro-inflammatory conditions.
Nature reviews. Rheumatology. 2025 May; 21(May):275-290. doi: 10.1038/s41584-025-01240-x. pii: .
Base: PUBMEDEffectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Rheumatology (Oxford, England). 2025 May; 64(May):2385-2394. doi: 10.1093/rheumatology/keae707. pii: .
Base: PUBMEDThe British Society for Rheumatology guideline for the management of foot health in inflammatory arthritis.
Rheumatology (Oxford, England). 2025 May; 64(May):2355-2368. doi: 10.1093/rheumatology/keaf071. pii: .
Base: PUBMEDSafety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study.
The Lancet. Rheumatology. 2025 Apr; 7(Apr):e226-e229. doi: 10.1016/S2665-9913(24)00402-8. pii: S2665-9913(24)00402-8.
Base: PUBMEDRheumatologic complications of CAR-T Cell therapy. Experience of a single center.
Seminars in arthritis and rheumatism. 2025 Apr; 71(Apr):152610. doi: 10.1016/j.semarthrit.2024.152610. pii: S0049-0172(24)00250-6.
Base: PUBMEDDelineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.
Nature reviews. Rheumatology. 2025 Apr; 21(Apr):237-248. doi: 10.1038/s41584-025-01229-6. pii: .
Base: PUBMEDWhat is rheumatoid factor? From screening to personalized management.
Rheumatology (Oxford, England). 2025 Mar; 64(Mar):ii9-ii14. doi: 10.1093/rheumatology/keaf003. pii: .
Base: PUBMEDEuropean expert recommendations for managing systemic sclerosis and its complications.
Nature reviews. Rheumatology. 2025 Mar; 21(Mar):133-134. doi: 10.1038/s41584-024-01205-6. pii: .
Base: PUBMEDBrazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases.
Advances in rheumatology (London, England). 2025 Mar; 65(Mar):18. doi: 10.1186/s42358-025-00449-4. pii: .
Base: PUBMEDInternational Consensus Guidance for the Management of Glucocorticoid Related Complications in Neuromuscular Disease.
Muscle & nerve. 2025 Mar; 71(Mar):309-316. doi: 10.1002/mus.28328. pii: .
Base: PUBMEDPediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.
Clinical rheumatology. 2025 Mar; 44(Mar):901-922. doi: 10.1007/s10067-025-07334-x. pii: .
Base: PUBMEDEnhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel.
Rheumatology (Oxford, England). 2025 Feb; 64(Feb):561-573. doi: 10.1093/rheumatology/keae172. pii: .
Base: PUBMEDBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.
Rheumatology (Oxford, England). 2025 Feb; 64(Feb):409-439. doi: 10.1093/rheumatology/keae152. pii: .
Base: PUBMEDThe 2024 British Society for Rheumatology guideline for management of systemic sclerosis.
Rheumatology (Oxford, England). 2024 Nov; 63(Nov):2956-2975. doi: 10.1093/rheumatology/keae394. pii: .
Base: PUBMEDThe 2024 APLAR Consensus on the Management of Lupus Nephritis.
International journal of rheumatic diseases. 2025 Jan; 28(Jan):e70021. doi: 10.1111/1756-185X.70021. pii: .
Base: PUBMEDBritish Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024.
Rheumatology (Oxford, England). 2025 Jan; 64(Jan):74-90. doi: 10.1093/rheumatology/keae438. pii: .
Base: PUBMEDScreening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.
JAMA. 2025 Feb; 333(Feb):498-508. doi: 10.1001/jama.2024.27154. pii: .
Base: PUBMED2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis.
Arthritis care & research. 2023 Aug; 75(Aug):1603-1615. doi: 10.1002/acr.25117. pii: .
Base: PUBMEDExpert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults.
Annals of the rheumatic diseases. 2024 Nov; doi: 10.1136/ard-2024-226446. pii: ard-2024-226446.
Base: PUBMEDGlobal RA treatment recommendations: An update from the various international societies.
Best practice & research. Clinical rheumatology. 2024 Nov; 102019. doi: 10.1016/j.berh.2024.102019. pii: S1521-6942(24)00090-1.
Base: PUBMEDTreatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results.
Current opinion in rheumatology. 2024 Nov; 36(Nov):420-426. doi: 10.1097/BOR.0000000000001049. pii: .
Base: PUBMEDDisease activity score for still's disease.
Clinical rheumatology. 2024 Nov; 43(Nov):3273-3283. doi: 10.1007/s10067-024-07127-8. pii: .
Base: PUBMEDEfficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
Annals of the rheumatic diseases. 2024 Nov; 83(Nov):1731-1747. doi: 10.1136/ard-2024-225854. pii: .
Base: PUBMEDThe 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summary.
Rheumatology (Oxford, England). 2024 Nov; 63(Nov):2948-2955. doi: 10.1093/rheumatology/keae390. pii: .
Base: PUBMEDProactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.
BMJ (Clinical research ed.). 2024 Oct; 387(Oct):e079830. doi: 10.1136/bmj-2024-079830. pii: .
Base: PUBMEDEULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.
Annals of the rheumatic diseases. 2024 Nov; 83(Nov):1614-1627. doi: 10.1136/ard-2024-225851. pii: .
Base: PUBMEDEULAR recommendations for the treatment of systemic sclerosis: 2023 update.
Annals of the rheumatic diseases. 2024 Oct; doi: 10.1136/ard-2024-226430. pii: ard-2024-226430.
Base: PUBMEDA clinical practice guideline for the management of the foot and ankle in rheumatoid arthritis.
Rheumatology international. 2024 Aug; 44(Aug):1381-1393. doi: 10.1007/s00296-024-05633-1. pii: .
Base: PUBMED2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.
Advances in rheumatology (London, England). 2024 Jul; 64(Jul):52. doi: 10.1186/s42358-024-00392-w. pii: .
Base: PUBMEDII Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.
Advances in rheumatology (London, England). 2024 Jun; 64(Jun):48. doi: 10.1186/s42358-024-00386-8. pii: .
Base: PUBMED2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Arthritis & rheumatology (Hoboken, N.J.). 2024 Aug; 76(Aug):1182-1200. doi: 10.1002/art.42861. pii: .
Base: PUBMED2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Arthritis & rheumatology (Hoboken, N.J.). 2024 Aug; 76(Aug):1201-1213. doi: 10.1002/art.42860. pii: .
Base: PUBMEDJuvenile Idiopathic Arthritis.
The New England journal of medicine. 2025 Jul; 393(Jul):162-174. doi: 10.1056/NEJMra2402073. pii: .
Base: PUBMEDA Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
The New England journal of medicine. 2025 May; 392(May):2013-2024. doi: 10.1056/NEJMoa2413449. pii: .
Base: PUBMEDThe safety of low-dose methotrexate for rheumatic diseases: looking beyond blood monitoring.
Rheumatology (Oxford, England). 2025 May; doi: 10.1093/rheumatology/keaf257. pii: keaf257.
Base: PUBMEDMusculoskeletal manifestations in leprosy.
Best practice & research. Clinical rheumatology. 2025 May; 39(May):102039. doi: 10.1016/j.berh.2025.102039. pii: S1521-6942(25)00007-5.
Base: PUBMEDTropical pyomyositis.
Best practice & research. Clinical rheumatology. 2025 May; 39(May):102041. doi: 10.1016/j.berh.2025.102041. pii: S1521-6942(25)00009-9.
Base: PUBMEDAn update on the pathogenesis of idiopathic inflammatory myopathies.
Current opinion in rheumatology. 2025 May; 37(May):192-198. doi: 10.1097/BOR.0000000000001077. pii: .
Base: PUBMEDAutoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Rheumatic diseases clinics of North America. 2025 May; 51(May):347-359. doi: 10.1016/j.rdc.2025.01.008. pii: S0889-857X(25)00008-0.
Base: PUBMEDEffectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Rheumatology (Oxford, England). 2025 May; 64(May):2385-2394. doi: 10.1093/rheumatology/keae707. pii: .
Base: PUBMEDManagement of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies.
Current opinion in rheumatology. 2025 May; 37(May):167-175. doi: 10.1097/BOR.0000000000001082. pii: .
Base: PUBMEDArthritis related to parasitic infections.
Best practice & research. Clinical rheumatology. 2025 May; 39(May):102062. doi: 10.1016/j.berh.2025.102062. pii: S1521-6942(25)00030-0.
Base: PUBMED